• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Silence Therapeutics Plc (Amendment)

    3/27/24 5:07:27 PM ET
    $SLN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SLN alert in real time by email
    SC 13D/A 1 d792279dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 4)*

     

     

    Silence Therapeutics plc

    (Name of Issuer)

    Ordinary Shares, nominal value £0.05 per share

    (Title of Class of Securities)

    G8128Y157

    (CUSIP Number)

    Richard Griffiths

    Floor 1 Liberation Station

    Esplanade, St Helier, Jersey, JE2 3AS

    Tel: +44 1534 719761

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    March 27, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

     

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


     (1)    

     Names of reporting persons

     

     Richard Ian Griffiths

     (2)  

     Check the appropriate box if a member of a group (see instructions)

     (a) ☐  (b) ☐

     

     (3)  

     SEC use only

     

     (4)  

     Source of funds (see instructions)

     

     PF

     (5)  

     Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

     (6)  

     Citizenship or place of organization

     

     Jersey, Channel Islands

    Number of

    shares  beneficially 

    owned by

    each

    reporting

    person

    with:

     

        (7)     

     Sole voting power

     

     23,709,102*

        (8)   

     Shared voting power

     

     0

        (9)   

     Sole dispositive power

     

     23,709,102*

       (10)   

     Shared dispositive power

     

     0

    (11)    

     Aggregate amount beneficially owned by each reporting person

     

     23,709,102*

    (12)  

     Check if the aggregate amount in Row (11) excludes certain shares (see instructions)

     

     ☐

    (13)  

     Percent of class represented by amount in Row (11)

     

     16.9%**

    (14)  

     Type of reporting person (see instructions)

     

     IN

     

    *

    Consists of (i) 10,923,969 ordinary shares represented by American Depositary Shares (“ADSs”) held by Ora Capital Limited; (ii) 1,860,714 ordinary shares represented by ADSs held by Sarossa Plc; (iii) 314,409 ordinary shares represented by ADSs held by Cream Capital Limited; and (iv) 10,610,010 ordinary shares represented by ADSs held by Mr. Griffiths. Each ADS represents, and at the holder’s option is convertible into, three ordinary shares of the Issuer. Mr. Griffiths is a director and the controlling shareholder of each of Ora Capital Limited, Sarossa Plc and Cream Capital Limited and possesses the power to direct the voting and disposition of these securities.

    **

    This percentage is calculated based upon the 139,506,817 outstanding ordinary shares of the Issuer (including ordinary shares in the form of ADSs), as disclosed in the Issuer’s Annual Report on Form 20-F, filed with the Securities and Exchange Commission on March 13, 2024.


     (1)    

     Names of reporting persons

     

     Ora Capital Limited

     (2)  

     Check the appropriate box if a member of a group (see instructions)

     (a) ☐  (b) ☐

     

     (3)  

     SEC use only

     

     (4)  

     Source of funds (see instructions)

     

     WC

     (5)  

     Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

     (6)  

     Citizenship or place of organization

     

     Jersey, Channel Islands

    Number of

    shares  beneficially 

    owned by

    each

    reporting

    person

    with:

     

        (7)     

     Sole voting power

     

     10,923,969*

        (8)   

     Shared voting power

     

     0

        (9)   

     Sole dispositive power

     

     10,923,969*

       (10)   

     Shared dispositive power

     

     0

    (11)    

     Aggregate amount beneficially owned by each reporting person

     

     10,923,969*

    (12)  

     Check if the aggregate amount in Row (11) excludes certain shares (see instructions)

     

     ☐

    (13)  

     Percent of class represented by amount in Row (11)

     

     7.8%**

    (14)  

     Type of reporting person (see instructions)

     

     CO

     

    *

    Consists of 10,923,969 ordinary shares represented by ADSs held by Ora Capital Limited.

    **

    This percentage is calculated based upon the 139,506,817 outstanding ordinary shares of the Issuer (including ordinary shares in the form of ADSs), as disclosed in the Issuer’s Annual Report on Form 20-F, filed with the Securities and Exchange Commission on March 13, 2024.


    Explanatory Note

    This Amendment No. 4 to Schedule 13D (this “Amendment”), which amends and supplements the Schedule 13D filed with the Securities and Exchange Commission (the “SEC”) on June 15, 2022, as amended on July 20, 2022, October 20, 2022, and August 14, 2023 (the “Schedule 13D”) on behalf of Richard Ian Griffiths, relates to the ordinary shares, nominal value £0.05 per share (the “Ordinary Shares”), of Silence Therapeutics plc (the “Issuer”) and includes Ordinary Shares in the form of American Depositary Shares or (“ADSs”). This Amendment is being filed to reflect the open market transactions of the Issuer’s ADSs by the Reporting Person together with dilution as a result of an increase in the share capital of the Issuer. Except as amended and supplemented hereby, the Schedule 13D remains in full force and effect. All capitalized terms used in this Amendment but not defined herein shall have the meanings ascribed thereto in the Schedule 13D.

     

    Item 2.

    Identity and Background

    Item 2 is hereby amended and restates as follows:

     

    (a)

    This Schedule 13D is filed by Richard Ian Griffiths (“Mr. Griffiths”) and Ora Capital Limited (“Ora” and, with Mr. Griffiths, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

     

    (b)

    The principal business office of the Reporting Persons is Floor 1 Liberation Station, Esplanade, St Helier, Jersey, JE2 3AS.

     

    (c)

    The principal business of Ora is capital investments. The principal business of Mr. Griffiths is serving as chairman of Sarossa Plc and Ora Limited.

     

    (d)

    During the last five years, none of the Reporting Persons has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

     

    (e)

    During the last five years, none of the Reporting Persons was a party to a civil proceeding of a judicial of administrative body of competent jurisdiction or were subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    (f)

    Ora was organized under the laws of Jersey and Mr. Griffiths is a citizen of Jersey, Channel Islands.

     

    Item 3.

    Source and Amount of Funds or Other Consideration

    Item 3 is hereby amended and supplemented as follows:

    Mr. Griffiths sold an aggregate of 1,870,182 ADSs in open market transactions between August 20, 2023 and March 27, 2024 for aggregate gross proceeds of $38.7M. Mr. Griffiths purchased an aggregate of 199,131 ADSs in open market transactions between August 22, 2023 and January 30, 2024 for an aggregate price of $1.4M. All purchases were for cash and were funded by personal funds of Mr. Griffiths.

     

    Item 5.

    Interest in Securities of the Issuer

    Item 5 is hereby amended and restated as follows:

     

    (a)-(b)

    Rows (7) through (13) of the cover pages of this Schedule 13D are hereby incorporated by reference.

     

    (c)

    Except as set forth in Schedule 1, none of the Reporting Persons has effected any transactions in the Issuer’s Ordinary Shares or ADSs during the last 60 days.

     

    (d)

    No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, the Ordinary Shares or ADSs beneficially owned by any of the Reporting Persons.

     

    (e)

    Not applicable.


    Item 7.

    Material to be Filed as Exhibits

    Item 7 is hereby amended and restated as follows:

     

    A.

    Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.


    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: March 27, 2024 

     

    Ora Capital Limited
    By:  

    /s/ Richard Ian Griffiths

      Name: Richard Ian Griffiths
      Title: Director
    Richard Ian Griffiths

    /s/ Richard Ian Griffiths


    Schedule 1

    Transactions in ADSs During the Past Sixty Days

     

    Date

      

    Nature of the

    Transaction

      

    Reporting Person

       Amount of
    Securities
    Purchased/Sold
        Price  

    01/26/24

       Purchase    Richard Griffiths      3,000     $ 18.70  

    01/29/24

       Purchase    Richard Griffiths      5,400     $ 19.06  

    01/30/24

       Purchase    Richard Griffiths      1,512     $ 18.90  

    02/07/24

       Sale    Richard Griffiths      (20,670 )    $ 16.65  

    02/08/24

       Sale    Richard Griffiths      (330,000 )    $ 16.58  

    02/23/24

       Sale    Richard Griffiths      (48,965 )    $ 18.63  

    02/26/24

       Sale    Richard Griffiths      (131,547 )    $ 18.53  

    02/27/24

       Sale    Richard Griffiths      (25,000 )    $ 24.84  

    02/27/24

       Sale    Richard Griffiths      (100 )    $ 18.87  

    02/27/24

       Sale    Richard Griffiths      (88,097 )    $ 19.31  

    02/28/24

       Sale    Richard Griffiths      (36,122 )    $ 24.84  

    02/28/24

       Sale    Richard Griffiths      (49,348 )    $ 25.59  

    02/28/24

       Sale    Richard Griffiths      (248,000 )    $ 20.14  

    02/29/24

       Sale    Richard Griffiths      (63,723 )    $ 25.67  

    02/29/24

       Sale    Richard Griffiths      (26,113 )    $ 25.40  

    02/29/24

       Sale    Richard Griffiths      (58,694 )    $ 20.14  

    03/01/24

       Sale    Richard Griffiths      (58,754 )    $ 25.44  

    03/01/24

       Sale    Richard Griffiths      (25,000 )    $ 25.45  

    03/01/24

       Sale    Richard Griffiths      (62,811 )    $ 20.12  

    03/04/24

       Sale    Richard Griffiths      (41,513 )    $ 25.47  

    03/04/24

       Sale    Richard Griffiths      (25,000 )    $ 20.47  

    03/05/24

       Sale    Richard Griffiths      (25,672 )    $ 25.88  

    03/05/24

       Sale    Richard Griffiths      (1,621 )    $ 20.19  

    03/06/24

       Sale    Richard Griffiths      (2,476 )    $ 26.14  

    03/06/24

       Sale    Richard Griffiths      (2,670 )    $ 25.70  

    03/07/24

       Sale    Richard Griffiths      (7,954 )    $ 25.68  

    03/07/24

       Sale    Richard Griffiths      (27,687 )    $ 24.67  

    03/08/24

       Sale    Richard Griffiths      (29,201 )    $ 25.92  

    03/11/24

       Sale    Richard Griffiths      (7,606 )    $ 26.13  

    03/11/24

       Sale    Richard Griffiths      (4,609 )    $ 24.70  

    03/12/24

       Sale    Richard Griffiths      (10,972 )    $ 24.68  

    03/13/24

       Sale    Richard Griffiths      (103,322 )    $ 22.74  

    03/13/24

       Sale    Richard Griffiths      (35,171 )    $ 25.30  

    03/13/24

       Sale    Richard Griffiths      (3,294 )    $ 22.75  

    03/13/24

       Sale    Richard Griffiths      (17,861 )    $ 25.36  

    03/14/24

       Sale    Richard Griffiths      (4,098 )    $ 25.79  

    03/15/24

       Sale    Richard Griffiths      (16,636 )    $ 23.97  

    03/19/24

       Sale    Richard Griffiths      (26,811 )    $ 23.71  

    03/20/24

       Sale    Richard Griffiths      (5,158 )    $ 23.07  

    03/22/24

       Sale    Richard Griffiths      (27,842 )    $ 22.60  

    03/25/24

       Sale    Richard Griffiths      (30,000 )    $ 22.04  

    03/26/24

       Sale    Richard Griffiths      (35,000 )    $ 21.63  

    03/27/24

       Sale    Richard Griffiths      (35,580 )    $ 21.70  

    03/27/24

       Sale    Richard Griffiths      (15,000 )    $ 21.72  


    Exhibit(s):

    A - Joint Filing Agreement

    Get the next $SLN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SLN

    DatePrice TargetRatingAnalyst
    2/11/2025$6.00Sell
    Goldman
    12/2/2024Outperform
    BMO Capital Markets
    9/3/2024$40.00Buy
    Jefferies
    1/31/2024$67.00Outperform
    BMO Capital Markets
    5/8/2023$20.00Overweight
    Morgan Stanley
    12/9/2022$18.00Equal-Weight
    Morgan Stanley
    3/31/2022$33.00Buy
    Chardan Capital Markets
    More analyst ratings

    $SLN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

      Company further extends cash guidance into 2028 Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the first quarter ended March 31, 2025, and reviewed recent business highlights. "Silence delivered another strong quarter focused on clinical and operational execution," said Craig Tooman, President and Chief Executive Officer at Silence. "We remain focused on advancing enrollment into the SANRECO Phase 2 study of divesiran, a first-in-class siRNA program in PV, and continue to be on-track to complete enrollment by the end of this year. We are a

      5/8/25 8:00:00 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Silence Therapeutics Welcomes Tim McInerney to Board of Directors

      Mr. McInerney brings over 30 years of industry experience spanning senior executive, finance and capital advisory roles in the pharmaceutical and biotechnology sectors Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced the appointment of Tim McInerney to the Company's Board of Directors, effective immediately. Mr. McInerney will stand for re-appointment to the Silence Board at the Annual General Meeting ("AGM") in June 2025. "We are thrilled to welcome Tim to the Silence Board," said Iain Ross, Chairman of the Silence Board. "Tim is a seasoned executive and board memb

      5/6/25 7:45:00 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference

      Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that management will present a company overview at the Leerink Partners Global Healthcare Conference on Wednesday, March 12th at 1:00 p.m. ET. The live webcast can be accessed via the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcast will be available following the conference. About Silence Therapeutics Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people's lives by silencing diseases through precision engineer

      3/5/25 8:00:00 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLN
    Leadership Updates

    Live Leadership Updates

    See more
    • Silence Therapeutics Welcomes Tim McInerney to Board of Directors

      Mr. McInerney brings over 30 years of industry experience spanning senior executive, finance and capital advisory roles in the pharmaceutical and biotechnology sectors Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced the appointment of Tim McInerney to the Company's Board of Directors, effective immediately. Mr. McInerney will stand for re-appointment to the Silence Board at the Annual General Meeting ("AGM") in June 2025. "We are thrilled to welcome Tim to the Silence Board," said Iain Ross, Chairman of the Silence Board. "Tim is a seasoned executive and board memb

      5/6/25 7:45:00 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors

      Silence Therapeutics plc (NASDAQ:SLN) ("Silence" or the "Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced that Alistair Gray, who has served as an independent member of Silence's Board of Directors (the "Board") since 2015, informed the Company that he will retire from the Board, effective May 1, 2024. Iain Ross, Silence's Chairman of the Board, commented, "Alistair has made significant contributions to the Board and the Company over the past nine years. During his time on the Board, the Company has transitioned into a global player focused on the developmen

      4/29/24 8:30:00 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Silence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and Development

      Dr. Romano will succeed Dr. Giles Campion, CMO and Head of R&D, following his retirement by year-end Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced the appointment of Steven Romano, MD, as incoming Chief Medical Officer and Head of Research and Development. Dr. Romano will join Silence on April 1, 2023, and work alongside Giles Campion, MD, current CMO and Head of R&D at Silence, to ensure an efficient and smooth transition for Dr. Campion's retirement by year-end. Dr. Romano has served as non-execut

      3/28/23 7:05:00 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLN
    SEC Filings

    See more
    • SEC Form DEF 14A filed by Silence Therapeutics Plc

      DEF 14A - Silence Therapeutics plc (0001479615) (Filer)

      5/16/25 6:05:34 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Silence Therapeutics Plc

      SCHEDULE 13G/A - Silence Therapeutics plc (0001479615) (Subject)

      5/15/25 9:02:25 PM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Silence Therapeutics Plc

      10-Q - Silence Therapeutics plc (0001479615) (Filer)

      5/8/25 8:35:12 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Large owner Griffiths Richard Ian

      4 - Silence Therapeutics plc (0001479615) (Issuer)

      5/21/25 6:49:38 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Mcinerney Timothy

      4 - Silence Therapeutics plc (0001479615) (Issuer)

      5/20/25 4:14:11 PM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Mcinerney Timothy

      3 - Silence Therapeutics plc (0001479615) (Issuer)

      5/20/25 4:12:58 PM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $SLN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Goldman initiated coverage on Silence Therapeutics with a new price target

      Goldman initiated coverage of Silence Therapeutics with a rating of Sell and set a new price target of $6.00

      2/11/25 7:12:20 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BMO Capital Markets reiterated coverage on Silence Therapeutics

      BMO Capital Markets reiterated coverage of Silence Therapeutics with a rating of Outperform

      12/2/24 10:09:42 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Silence Therapeutics with a new price target

      Jefferies initiated coverage of Silence Therapeutics with a rating of Buy and set a new price target of $40.00

      9/3/24 8:14:09 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Silence Therapeutics Plc

      SC 13G/A - Silence Therapeutics plc (0001479615) (Subject)

      11/14/24 1:13:14 PM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Silence Therapeutics Plc

      SC 13G/A - Silence Therapeutics plc (0001479615) (Subject)

      11/14/24 9:44:01 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Silence Therapeutics Plc

      SC 13G/A - Silence Therapeutics plc (0001479615) (Subject)

      11/12/24 4:31:49 PM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLN
    Financials

    Live finance-specific insights

    See more
    • Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

      The Company's cash guidance is now extended into 2027 Company to host conference call and webcast today at 8 a.m. EST / 1 p.m. GMT Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the full year ended December 31, 2024, and provided a business update. "2024 was marked by strong clinical execution and pipeline advancement, highlighting the broad potential of our mRNAi GOLD™ platform to silence disease causing genes," said Craig Tooman, President and CEO of Silence. "In 2025, we are prioritizing investment in programs targeting rare conditi

      2/27/25 7:30:00 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025

      Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that the Company will release its financial and business results for the fourth quarter and full year ended December 31, 2024, on Thursday, February 27, 2025. Management will host a conference call at 8:00 a.m. ET / 1:00 p.m. GMT that day to discuss the Company's financial results and provide a general business update. The conference call will be webcast live and available on the Investors section of the Silence website at www.silence-therapeutics.com. The webcast will also be archived on the Company's website. Deta

      2/13/25 8:00:00 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients

      Divesiran eliminated the need for phlebotomy in all well-controlled patients following infrequent dosing and was well tolerated Data support advancing divesiran into Phase 2 Company to host conference call today at 8:30am Eastern Time Silence Therapeutics plc ("Silence" or the "Company"), (NASDAQ:SLN), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced positive results from the ongoing SANRECO Phase 1 repeat dose study of divesiran (SLN124), a siRNA (short interfering RNA) targeting TMPRSS6, in patients with polycythemia vera (PV). "With today's very exciting PV da

      6/27/24 7:30:00 AM ET
      $SLN
      Biotechnology: Pharmaceutical Preparations
      Health Care